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Lassa fever is a signiﬁcant health threat to West African human populations with hundreds of thousands
of annual cases. There are no approved medical countermeasures currently available. Compassionate use
of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success
depending on when administered or the donor source, respectively. We previously identiﬁed several
recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong
neutralization proﬁles in vitro. Here, we demonstrate remarkable therapeutic efﬁcacy using ﬁrst-in-class
human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment
alternative.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Lassa Fever (LF) is a major public health problem in Western
Africa where hundreds of thousands of infections are estimated to
occur annually. For those who present to a hospital for treatment
and are referred to a ward speciﬁc for the treatment of viral hem-
orrhagic fevers, the mortality rate approaches 70% (Shaffer et al.,
2014). Elevated mortality, environmental stability that favors arti-
ﬁcial aerosol infection, and a dearth of medical countermeasures
for LF also make Lassa virus a clear biodefense concern (Stephenson
et al., 1984). The nucleoside analog ribavirin, convalescent sera, and
supportive therapy are the only treatments options currently in use
for LF. Safety proﬁle concerns, lack of controlled and randomized
clinical studies, and short window of efﬁcacy for therapeuticl Branch, Galveston National
-0610, USA.
t).
B.V. This is an open access article uribavirin or convalescent sera use in LF patients support the need
for development of alternative and robust therapeutic options
(Bausch et al., 2010). Single monoclonal antibody therapies against
viral agents have recently proven highly effective; however, only
one has been approved for use in humans (Mejias and Ramilo,
2008). The 2013e2016 Ebola hemorrhagic fever epidemic in West
Africa has, however, potentiated the accelerated development and
clinical evaluation of ZMapp, a cocktail of three chimeric mono-
clonal antibodies against distinct epitopes on the Ebola virus
glycoprotein (McCarthy, 2014).
Since 2008, the Viral Hemorrhagic Fever Consortium (http://
www.VHFC.org) has concentrated efforts at characterizing protec-
tive or pathogenic roles of B cells in LF directly fromhuman patients
(Robinson et al., 2016). This work has resulted in the derivation of
the largest known collection of fully human monoclonal antibodies
(huMAbs) from convalescent West African LF patients. Here, we
describe the protective efﬁcacy of select LASV glycoprotein speciﬁc
huMAbs in vivo where a panel of 11 huMAbs targeting thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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guinea pig (GP) model of LF based on their in vitro neutralization
proﬁles.
Optimized bicistronic IgG1 backbone vectors for high level,
transient expression in mammalian cells were used to generate
huMAbs for therapeutic evaluation in vitro and in a GP model of LF.
Scaled production of antibodies for in vivo studies is detailed in the
supplementary materials. Antibodies for therapeutic studies were
formulated in a buffer for injection at >20 mg/mL, and assayed for
purity, concentration, identity, and endotoxin levels prior to lot
release.
A panel of 125 independently derived LASV glycoprotein-
speciﬁc huMAbs were extensively characterized for binding,
epitope grouping, and neutralization potential in vitro (Robinson
et al., 2016). Eleven huMAbs consistently registered greater than
50% neutralization in a lentiviral entry assay system pseudotyped
with the LASV (Josiah strain, Clade IV) GPC, a lymphocytic chorio-
meningitis virus (LCMV) backbone pseudotyped with LASV GPC, or
in a live LASV plaque reduction neutralization test (PRNT)
(Robinson et al., 2016).
Antibodies segregated into two distinct performance clusters of
IC50 and IC80 values (Supplemental Table 1, Fig.1A, B). Neutralizing
antibodies (NAbs) 37.2D, 8.9F, 12.1F, 37.7H, 25.6A, 36.1F, and 25.10C
clustered in the lowest combined Log10 IC50 (Fig. 1A.) and Log10
IC80 (Fig. 1B.) values range. A second cluster of NAbs comprised of
19.7E, 10.4B, 37.2G, and 2.9D recorded signiﬁcantly combined
higher Log10 IC50 and Log10 IC80 values range (Fig. 1A, B). Ten of
the 11 huMAbs bound mammalian cell-generated LASV glycopro-
tein immobilized on ELISA plates. The single exception, huMAb 8.9F
was identiﬁed via a pseudovirus neutralization assay performed as
previously reported (Robinson et al., 2016), and did not bind puri-
ﬁed glycoprotein in ELISA.
Binding efﬁcacy to different clades of LASV was assessed using
ﬂow cytometry to detect the glycoprotein complex (GPC) genes of
LASV Josiah (Clade IV), and Nigerian strains NigA19-08 (Clade III)
and NigA18-237 (Clade II) which were transiently expressed on the
surface of transfected HEK-293T/17 cells for 24 h prior to ﬂow
cytometric analysis (FACS). Histogramswere generated that display
the log ﬂuorescence intensity for each antibody bound to GPC on
the surface of live transfected cells. All 11 huMAbs bound to HEK-
293T/17 cell surface-expressed LASV GPC by ﬂow cytometry
(Fig.1C). Three LASV huMAbs (8.9F,12.1F, and 37.2D) also bound cell
surface expressed GPCs from Clade II (strain Nig A18-237) and III
(strain Nig A19-08) strains (Fig. 1C, D). These binding proﬁles sug-
gest that these 3 LASV huMAbs may have therapeutic utility across
LASV Clades. These data guided the identiﬁcation and prioritization
of leading candidate therapeutic huMAbs for in vivo studies.
Animal studies were completed under biosafety level (BSL)-4
biocontainment at the Galveston National Laboratory and were
approved by the University of Texas Medical Branch Institutional
Laboratory Animal Care and Use Committee. Female outbred
Hartley strain GP (~350e400 g, ~5e6 weeks old, Harlan Sprague
Dawley, Houston, TX) were acclimatized for ~1 week prior to
challenge intraperitoneally (IP) with 1000 plaque forming units of
guinea pig adapted (GPA) LASV-Josiah (N¼ 5/treatment group). The
GPA LASV infection model of outbred Hartley GP has been
described recently for testing therapeutics against LASV (Safronetz
et al., 2015). The advantage of using outbred animals to model
human infection is inferred from the higher variability of immune
responsiveness inherent in outbred populations allowing for
increased countermeasure testing stringency versus those inbred
for genetically tractable immune deﬁciencies which may, in turn,
result in reduced predictive efﬁcacy of the treatment in question by
only testing a single immune phenotype rather than multiple at
one time, as would be present in an outbred test population.Animals were administered huMAbs (30 mg/kg of body weight)
IP immediately after challenge (day 0) and on days 3 and 6 post
infection (PI). Control animals were not treated. Guinea pigs were
monitored for clinical observations, appearance, behavior, activity,
and signs of paresis. Clinical scores were determined as Bright,
Alert, Responsive ¼ 0, Rough ¼ 4, Sick ¼ 8, Moribund ¼ 12, or
Expired ¼ 16 over the course of 28 days after which survivors were
euthanized at the study endpoint per IACUC protocol. Animals
which were scored rough had roughed fur, delayed responsiveness,
and some evidence of weight loss. Sick animals had marked lack of
grooming, unstable gait, and clear evidence of weight loss. Blood
was collected into EDTA containing tubes on days 7 and 14 and
viremia was assessed from separated plasma using classical titra-
tion methods as outlined in supplemental materials. Kaplan-Meier
survival curves were generated in Prism 5 and survival curves were
compared using Log-rank (Mantel-Cox) test (GraphPad Software, La
Jolla, CA) for treated groups versus untreated controls for each
study (Fig. 2A).
Eleven LASV huMAbs tested in a Hartley GP model of LF segre-
gated the antibodies into three distinct protection groups. One
group of huMAbs, 25.6A, 2.9D, 8.9F,12.1F, and 37.7H conferred 100%
protection and no change in clinical score in GPs. In a second group,
37.2D, 19.7E, and 37.2G protected 80e90% of animals. A third group
comprised of 10.4B, 25.10C, and 36.1F, conferred 40, 30, and 20%
protection, respectively. An irrelevant recombinant human isotype
control (IgG1) antibody did not confer protection (0% survival).
From the tested antibodies, no signiﬁcant differences were
observed between protection level and epitope groups; however,
more antibodies from each respective treatment group will need to
be tested in order to verify the potential importance of any one
particular epitope group in regard to protection (Supplemental
Table 1).
The combined in vitro IC50 and IC80 data generally correlated
well with protection in vivo for the top tier antibodies (100% pro-
tection). All but 2.9D neutralized pseudovirus in the nanomolar
range, and registered a PRNT IC50 mean of 13.6 nM. Despite
conferring 100% protection in GP huMAb 2.9D registered high IC50
values in vitro (Supplemental Table 1). 37.2D and 19.7E generated
distinct IC50 values in pseudovirus assays, with the former
neutralizing in the low nanomolar range, and the latter at >20 nM.
Both antibodies neutralized LASV in PRNT at IC50 ~ 18 nM, and
conferred 90% overall protection in GPs. It should be noted that
19.7E and 37.2D antibodies conferred 100% protection yet showed
some clinical signs in an initial study (5/5) so a repeat study was
performed where 80% (4/5) survived and similar clinical values
were observed.
37.2G protected 80% of animals tested, despite high IC50 values
in pseudovirus and PRNT assays (16.0 and >100 nM, respectively).
10.4B neutralized poorly in all assays and conferred only 40% pro-
tection in GPs. Surprisingly, the most potent antibody identiﬁed
in vitro, 25.10C, with subnanomolar activity in all pseudovirus
platforms, and 6.24 nM in PRNT, conferred an average 30% (3/10)
protection in GPs. In our initial assessment, 25.10C protected 40%
(2/5) of GPs, yet only 20% (1/5) in a repeat study. The difference in
results could be attributed to inherent immune variability of
outbred animals where differences in individual's susceptibility to
the virus contributes to disease course. Importantly, these data
indicate that in vitro neutralization assays have value in selecting
antibodies with protective efﬁcacy in vivo, but are not necessarily
predictive of levels of protection.
Viremia was compared by Kruskal-Wallis test supported by
Dunn's Multiple comparison posttest (Prism 5, GraphPad Software,
La Jolla, CA) to detect differences from the control group for time
points relevant to onset (day 7) or peak viremia (day 14) as deter-
mined from historical data (Geisbert, T.W. unpublished data).
Fig. 1. Correlation of IC50 and IC80 values among leading huMAb candidates in LASV neutralization assay platforms. Averaged, log10 transformed IC50 (A.) and IC80 (B.) values
for therapeutic candidate huMAbs derived in LASV/HIV-1pp, LASV/LCMVpp, and PRNT assays. Antibodies segregated into two distinct clusters of IC50 and IC80 values. (C.) FACS
binding proﬁles of NAbs (Red) to 293T cell surface-expressed LASV GPC (Josiah) versus irrelevant human IgG antibody isotype control (Black). LASV NAbs did not bind signiﬁcantly to
mock transfected 293T cells (data not shown). A potential therapeutic cocktail comprised of NAbs 8.9F, 12.1F, and 37.2D bound to 293T cells expressing GPC from clade III (D.) and
clade II (E.) strains of LASV, highlighting their relevance as potential Pan Lassa therapeutics.
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7 and 14, respectively. Despite 100% protection at the study
endpoint, some animals from treatment group 8.9F or 37.7H, 2.9D,
and 25.6A had low level viremia on day 7 or 14, respectively.
Treatment groups where 90% protection was afforded (37.2D and
19.7E) had reduced mean viremia titers and minimal clinical score
values. Treatment groups with 80% or less survival had comparable
mean viremia titers to control animals on day 7, but by day 14mean
viremia was markedly lower than control animals. Groups with
80e90% survival exhibited relatively low mean clinical scores and
all remaining treatment groups exhibited concomitant increases in
mean clinical scores with decreases in survival per group (Fig. 2B, C,
and Supplemental Fig. 1). Endpoint viremia was not determined for
these studies as survival was the primary metric of interest, though
all surviving animals demonstrated no clinical signs to indicate
disease was present at study endpoint 28 days PI (Fig. 2B and
Supplemental Fig. 1).
Lassa fever is a major public health threat in West Africa. Recentimportations of cases of LF to non-endemic regions of the world
illustrate the global public health threat (Amorosa et al., 2010; Haas
et al., 2003; Hirabayashi et al., 1989). Currently, no approved LF
vaccines or therapeutics exist, yet there is a clear public health need
in endemic regions. Further, LASV has been categorized as one of
the World Health Organization's top 10 emerging pathogens and
has thus created increased demand for medical countermeasures
(WHO, 2016). Off label use of Ribavirin can be partially effective in
the treatment of acute LF; however, it has a narrow window of
efﬁcacy, generally within 6 days following the onset of fever and is
often associated with marked side effects due to dosing regimen
(Bausch et al., 2010). Unfortunately, the drug has not demonstrated
great efﬁcacy in treating advanced LF (Bausch et al., 2010).
The current studies present a novel alternative for treating LF
infections that relies on the use of fully human antibodies derived
from convalescent donors. Early studies employing convalescent
plasma to treat active LF infections met with mixed success; this
was likely due to unreliable titers of protective antibodies in
Fig. 2. Protective efﬁcacy proﬁle of LASV GPC huMAbs in a Hartley GP model of LF. (A.) Pooled survival plots for treated and control GPs challenged with LASV from multiple
independent experiments, as noted. Control GPs succumbed to LF between 14 and 22 PI (median ¼ 15 days). In these studies a single GP survived infection through the 28-day study
endpoint (1/18). Hartley GPs challenged with GPA LASV strain Josiah on day 0 ( ) were treated with LASV huMAbs, at 30 mg/kg of body weight on the same day (↓). Additional
therapeutic antibody was administered at the same dose on days 3 and 6 PI (↓). Animals were monitored for clinical signs of LF throughout the 28-day study timeline. (B.) Viremia
data from treated and control GP plasma on days 7 and 14 PI. Viremia levels for day 7 treatment groups 37.7H, 12.1F, and 25.6A as well as day 14 12.1F, 37.2D, 19.7E, and 10.4B were
below the limit of detection (LOD). Error bars represent standard deviation from mean values. *denotes P  0.05. **denotes P  0.001. ***denotes P < 0.0001.
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against circulating LASV strains (Cummins et al., 1991; Jahrling
et al., 1985; Leifer et al., 1970). Here we show that the majority of
antibodies administered either individually or in combination
prevented development of active disease in GP when administered
soon after infection. These studies demonstrate the in vivo potential
of these antibodies and merit further preclinical development of
huMAbs as mono-therapies or cocktails for pre-exposure prophy-
laxis or post-exposure treatment in the gold standard animalmodel
for LF, non-human primates. This technology may be a particularly
relevant treatment for high risk scenarios such as caregivers
working directly with LF patients or those who have otherwise
become exposed to the virus in the community. In the absence of
approved vaccines, safe and effective immunotherapeutics would
provide a superior prophylactic and post-exposure treatment
alternative, with well tolerated proﬁles, and likely few metabolic
side effects.
The ongoing outbreak of LF in Nigeria and neighboring Benin,
endemicity of the disease in Sierra Leone, Guinea, and Liberia,potential for geographic expansion (Fichet-Calvet and Rogers,
2009) and threat to national security if developed as a bioweapon
should prioritize development of a new and safe class of Pan-Lassa
virus therapeutics (Ibekwe, 2012).
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